Hypoalbuminemia in Cirrhotic AscitesPhase 1NCT07851688
A Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of GLR1075 Injection in Healthy Trial Participants and Cirrhotic Trial Participants With Ascites and Hypoalbuminemia
A Phase 1 study testing Human Serum Albumin(HSA) and GLR1075 Injection in people with Hypoalbuminemia in Cirrhotic Ascites, run by Gan & Lee Pharmaceuticals. at 1 site in China.
Trial summary
This trial is conducted in China. This study plans to include 3 parts,Part A, a single ascending dose (SAD) study in healthy trial participants; Part B, a multiple dose (MD) study in healthy trial participants; and Part C, a multiple ascending dose (MAD) study in cirrhotic trial participants with ascites and… Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Hypoalbuminemia in Cirrhotic Ascites
- What is being tested?
- Human Serum Albumin(HSA) and GLR1075 Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 106 participants
- Where
- 1 siteChina
- Study dates
- 7 Oct 2026to 31 Dec 2028
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- PART A:
- Signed informed consent form (ICF) prior to the trial, with a full understanding of the trial content, procedures, and possible adverse reactions, and able to comply with the contraindications and restrictions specified in this protocol.
- At the time of informed consent, Male or female aged 18-55 years (inclusive)..
- At screening, body mass index (BMI) ≥18.5 and ≤26.0 kg/m², with body weight ≥50.0 kg for males and ≥45.0 kg for females.
- At screening and before randomization and dosing, women of childbearing potential must have a negative human chorionic gonadotropin (hCG) pregnancy test.
- From the time of signing the informed consent form until 90 days after administration of the investigational medicinal product, female trial participants of childbearing potential、male trial participants and their partners must agree to use reliable contraceptive measures, and trial participants must not donate eggs (oocytes, ova) or sperm for assisted reproductive purposes.
Show all 20Show fewer
- PART B：
- Signed informed consent form (ICF) prior to the trial, with a full understanding of the trial content, procedures, and possible adverse reactions, and able to comply with the contraindications and restrictions specified in this protocol.
- At the time of informed consent, Male or female aged 18-55 years (inclusive)..
- At screening, body mass index (BMI) ≥18.5 and ≤26.0 kg/m², with body weight ≥50.0 kg for males and ≥45.0 kg for females.
- At screening and before randomization and dosing, women of childbearing potential must have a negative human chorionic gonadotropin (hCG) pregnancy test.
- From the time of signing the informed consent form until 90 days after administration of the investigational medicinal product, female trial participants of childbearing potential、male trial participants and their partners must agree to use reliable contraceptive measures, and trial participants must not donate eggs (oocytes, ova) or sperm for assisted reproductive purposes.
- PART C:
- Signed informed consent form (ICF) prior to the trial, with a full understanding of the trial content, procedures, and possible adverse reactions, and able to comply with the contraindications and restrictions specified in this protocol.
- At the time of informed consent, Male or female aged 18-65 years (inclusive).
- At screening, body mass index (BMI) ≥18.5 and ≤28.0 kg/m².
- Diagnosed with cirrhotic ascites based on clinical, laboratory, or imaging findings in accordance with the 《Guidelines for the Diagnosis and Treatment of Cirrhotic Ascites (2023)》 issued by the Chinese Society of Hepatology, and abdominal ultrasound at screening confirms grade 1-2 ascites.
- Serum albumin ≤30 g/L at screening.
- At screening and before randomization/dosing, women of childbearing potential must have a negative human chorionic gonadotropin (hCG) pregnancy test.
- From the time of signing the informed consent form until 90 days after the last administration of the investigational medicinal product, female trial participants of childbearing potential and male trial participants and their partners must agree to use reliable contraceptive measures (see Appendix 1), and trial participants must not donate eggs (oocytes, ova) or sperm for assisted reproductive purposes.
Who cannot join
- PATR A:
- Individuals with an allergic constitution, or a history of allergic diseases such as bronchial asthma, urticaria, or eczema, or known allergy, hypersensitivity, or intolerance to the investigational medicinal product or similar products or their excipients, any human plasma-derived human albumin component.
- Individuals who are pregnant or breastfeeding at screening, or who plan to become pregnant during the trial.
- At screening or before randomization，individuals with clinically significant abnormalities, as judged by the investigator, in physical examination, vital signs, laboratory tests (complete blood count, urinalysis, blood chemistry, coagulation function), posteroanterior chest X-ray or chest CT, abdominal and urinary system ultrasound, 12-lead electrocardiogram, or other auxiliary examinations ;
- Individuals with diseases of the nervous system, endocrine system, cardiovascular system, respiratory system, hematologic system, immune system, psychiatric system, digestive system, abnormal liver function, abnormal renal function (eGFR <90 mL/min/1.73 m²), musculoskeletal system, or any other disease or physiological condition that could significantly alter the absorption, metabolism, or elimination of the drug, as well as individuals with suspected and/or confirmed history of tumors at screening or before randomization.
- .Individuals who have participated in another interventional clinical trial and received intervention within 3 months before screening (calculated from the last visit of the above clinical trial) or within 5 half-lives of other investigational medicinal products (whichever is longer); or who plan to participate in another clinical trial before completing all scheduled assessments in this trial.
Show all 42Show fewer
- Individuals with a history of drug abuse or drug addiction or with a positive drug abuse test within 1 year before screening.
- Individuals who consume more than 14 units of alcohol per week within 3 months before screening: 1 unit ≈ 360 mL beer, or 45 mL spirits, or 150 mL wine, or who cannot abstain from alcohol during the trial, or with a positive alcohol breath test at screening.
- Individuals who smoke more than 5 cigarettes per day within 3 months before screening, or who cannot stop using any tobacco products during the trial, or who consume tobacco products within 48 hours before randomization and dosing.
- Individuals who consume excessive tea, coffee, and/or caffeine-rich beverages (more than 8 cups per day, 1 cup ≈ 250 mL) daily within 3 months before screening.
- Individuals with a history of needle or blood phobia, or who cannot or are unwilling to undergo repeated venipuncture due to poor tolerance or difficult venous access.
- Individuals with any food allergy or special dietary requirements who cannot comply with a unified diet or dietary restrictions.
- Any reason that the investigator considers may prevent the trial participant from participating in the study.
- PART B：
- <!-- -->
- Individuals with an allergic constitution, or a history of allergic diseases such as bronchial asthma, urticaria, or eczema, or known allergy, hypersensitivity, or intolerance to the investigational medicinal product or similar products or their excipients, any human plasma-derived human albumin component.
- Individuals who are pregnant or breastfeeding at screening, or who plan to become pregnant during the trial.
- At screening or before randomization，individuals with clinically significant abnormalities, as judged by the investigator, in physical examination, vital signs, laboratory tests (complete blood count, urinalysis, blood chemistry, coagulation function), posteroanterior chest X-ray or chest CT, abdominal and urinary system ultrasound, 12-lead electrocardiogram, or other auxiliary examinations ;
- Individuals with diseases of the nervous system, endocrine system, cardiovascular system, respiratory system, hematologic system, immune system, psychiatric system, digestive system, abnormal liver function, abnormal renal function (eGFR <90 mL/min/1.73 m²), musculoskeletal system, or any other disease or physiological condition that could significantly alter the absorption, metabolism, or elimination of the drug, as well as individuals with suspected and/or confirmed history of tumors at screening or before randomization.
- .Individuals who have participated in another interventional clinical trial and received intervention within 3 months before screening (calculated from the last visit of the above clinical trial) or within 5 half-lives of other investigational medicinal products (whichever is longer); or who plan to participate in another clinical trial before completing all scheduled assessments in this trial.
- Individuals with a history of drug abuse or drug addiction or with a positive drug abuse test within 1 year before screening.
- Individuals who consume more than 14 units of alcohol per week within 3 months before screening: 1 unit ≈ 360 mL beer, or 45 mL spirits, or 150 mL wine, or who cannot abstain from alcohol during the trial, or with a positive alcohol breath test at screening.
- Individuals who smoke more than 5 cigarettes per day within 3 months before screening, or who cannot stop using any tobacco products during the trial, or who consume tobacco products within 48 hours before randomization and dosing.
- Individuals who consume excessive tea, coffee, and/or caffeine-rich beverages (more than 8 cups per day, 1 cup ≈ 250 mL) daily within 3 months before screening.
- Individuals with a history of needle or blood phobia, or who cannot or are unwilling to undergo repeated venipuncture due to poor tolerance or difficult venous access.
- Individuals with any food allergy or special dietary requirements who cannot comply with a unified diet or dietary restrictions.
- Any reason that the investigator considers may prevent the trial participant from participating in the study.
- PART C:
- <!-- -->
- Individuals with an allergic constitution, or a history of allergic diseases such as bronchial asthma, urticaria, or eczema, or known allergy, hypersensitivity, or intolerance to the investigational medicinal product or similar products or their excipients, any human plasma-derived human albumin component, or food allergy.
- Individuals who are pregnant or breastfeeding at screening, or who plan to become pregnant during the trial.
- Individuals with severe digestive system diseases and complications that the investigator considers unsuitable for participation in this study, including but not limited to Child-Pugh grade C at screening or before randomization, grade 3 or 4 hepatic encephalopathy
- Individuals with a history of malignant tumors within 5 years before screening (except for adequately treated or resected non-metastatic basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix).
- Individuals with severe cardiovascular and cerebrovascular events within 6 months before screening,
- Individuals with poorly controlled blood pressure at screening, defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg without medication or after stable medication.
- Individuals with any of the following abnormal laboratory and/or imaging findings at screening or before randomization:
- 1) Complete blood count: absolute neutrophil count <1.0×10⁹/L, platelets <30×10⁹/L, white blood cells <2.0×10⁹/L, hemoglobin <75 g/L; 2) Blood chemistry: ALT and/or AST >5.0× ULN, total bilirubin >3.0× ULN; eGFR <60 mL/min/1.73 m²; 3) Coagulation function: international normalized ratio (INR) >1.5; 4) Urinalysis: urine protein ≥1+ and the investigator determines that the participant is unsuitable for the trial; 8. Individuals with a history of drug abuse or drug addiction within 1 year before screening, or with positive alcohol breath test or drug abuse test at screening.
- 9. Individuals who consume more than 14 units of alcohol per week within 3 months before screening: 1 unit ≈ 360 mL beer, or 45 mL spirits, or 150 mL wine, or who cannot abstain from alcohol during the trial, or with a positive alcohol breath test at screening.
- 10. Individuals who smoke more than 5 cigarettes per day within 3 months before screening, or who cannot stop using any tobacco products during the trial.
- 11 Individuals who have participated in another interventional clinical trial and received intervention within 3 months before screening (calculated from the last visit of the above clinical trial) or within 5 half-lives of other investigational medicinal products (whichever is longer); or who plan to participate in another clinical trial before completing all scheduled assessments in this trial.
- 12. Individuals with a history of needle or blood phobia, or who cannot or are unwilling to undergo repeated venipuncture due to poor tolerance or difficult venous access.
- 13. Any reason that the investigator considers may prevent the trial participant from participating in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Yunda Zhuge contact
China1 site
Gan & Lee Pharmaceuticals
Beijing
chechen He, 010-56456739, chenchen.he@ganlee.com
About this study
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of GLR1075 Injection Following Single and Multiple Dosing in Healthy Trial Participants and Multiple Dosing in Cirrhotic Trial Participants With and Hypoalbuminemia
This trial is conducted in China. This study plans to include 3 parts,Part A, a single ascending dose (SAD) study in healthy trial participants; Part B, a multiple dose (MD) study in healthy trial participants; and Part C, a multiple ascending dose (MAD) study in cirrhotic trial participants with ascites and hypoproteinemia. All parts are intended to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of GLR1075.
- Conditions
- Hypoalbuminemia in Cirrhotic Ascites
- Being tested
- placebo GLR1075 Vehicle, Human Serum Albumin(HSA), GLR1075 Injection
- Keywords
- GLR1075 Injection;Cirrhotic Ascites; Hypoalbuminemia
- Medical subject headings
- Hypoalbuminemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
placebo GLR1075 VehicleDrug
Single dose of intravenous infusion
Human Serum Albumin(HSA)Drug
human albumin injection multiple doses of intravenous infusion
GLR1075 InjectionDrug
recombinant human albumin injection single dose or multiple doses of intravenous infusion
| Study group | Role | What they receive |
|---|---|---|
| placebo GLR1075 Vehicle | Placebo comparator | GLR1075 Vehicle Injection single dose Receives: Drug: placebo GLR1075 Vehicle |
| Human Serum Albumin(HSA) | Active comparator | GLR1075 Injection multiple doses of intravenous infusion Receives: Drug: Human Serum Albumin(HSA) |
| GLR1075 Injection | Experimental | recombinant human albumin Receives: Drug: GLR1075 Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of AEs, number of AE episodes, and incidence rate of AEs
Measured: Day1-Day 90 for PART A,Day1-Day 132 for PART B,Day1-Day 104 for PART C
Secondary outcomes (7)
Pharmacokinetics parameters-AUC0-t
Area under the plasma concentration-time curve from time 0 to last time of quantifiable concentration （AUC0-t）
Measured: Day 1-Day 90 for Part A,Day 1-Day132 for Part B
Pharmacokinetics parameters-Cmax
Maximum Plasma Concentration(Cmax)
Measured: Day 1-Day90 for Part A,Day 1-Day132 for Part B
Pharmacokinetics parameters-Tmax
time to Maximum Plasma Concentration（Tmax）
Measured: Day 1-Day 90 for Part A,Day 1-Day132 for Part B
Pharmacodynamic parameters-serum albumin
Change from baseline in serum albumin level
Measured: Day 1-Day 90 for Part A, Day 1-Day132 for Part B, Day 1-Day104 for Part C
Pharmacodynamic parameters-Plasma colloid osmotic pressure
Change from baseline in Plasma colloid osmotic pressure
Measured: Day 1-Day 30 for Part A,Day 1-Day102 for Part B,Day 1-Day104 for Part C
Efficacy end point-serum albumin level
The proportion of trial participants whose serum albumin level reached 35g/L during the treatment period
Measured: Day 1-Day15 for Part C
Immunogenicity-ADA
Anti-Drug antibody (ADA)
Measured: Day 1-Day 90 for Part A，Day 1-Day132 for Part B，Day 1-Day104 for Part C
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2026
- Study start7 Oct 2026 (estimated)
- Primary completion30 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hypoalbuminemia in Cirrhotic AscitesStudies of the same condition, open and under way.
- More trials run by Gan & Lee Pharmaceuticals.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 106 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gan & Lee Pharmaceuticals.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07851688
- Sponsor's protocol ID
- GLR1075-HCA-101
- Status last verified
- Sep 2026
- First submitted
- 18 Sep 2026
- Last updated
- 1 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of GLR1075 Injection Following Single and Multiple Dosing in Healthy Trial Participants and Multiple Dosing in Cirrhotic Trial Participants With and Hypoalbuminemia
- ClinicalTrials.gov ID
- NCT07851688
- Acronym / sponsor ID
- GLR1075-HCA-101
- Conditions
- Hypoalbuminemia in Cirrhotic Ascites
- Keywords
- GLR1075 Injection;Cirrhotic Ascites; Hypoalbuminemia
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 106 participants (estimated)
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry (pharma, biotech, devices)
- Study start
- 7 Oct 2026 (estimated)
- Primary completion
- 30 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 1 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial is conducted in China. This study plans to include 3 parts,Part A, a single ascending dose (SAD) study in healthy trial participants; Part B, a multiple dose (MD) study in healthy trial participants; and Part C, a multiple ascending dose (MAD) study in cirrhotic trial participants with ascites and hypoproteinemia. All parts are intended to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of GLR1075.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| placebo GLR1075 Vehicle | Placebo comparator | Drug: placebo GLR1075 VehicleGLR1075 Vehicle Injection single dose |
| Human Serum Albumin(HSA) | Active comparator | Drug: Human Serum Albumin(HSA)GLR1075 Injection multiple doses of intravenous infusion |
| GLR1075 Injection | Experimental | Drug: GLR1075 Injectionrecombinant human albumin |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (20 listed)
- PART A:
- PART B：
- Signed informed consent form (ICF) prior to the trial, with a full understanding of the trial content, procedures, and possible adverse reactions, and able to comply with the contraindications and restrictions specified in this protocol.
- At the time of informed consent, Male or female aged 18-55 years (inclusive)..
- At screening, body mass index (BMI) ≥18.5 and ≤26.0 kg/m², with body weight ≥50.0 kg for males and ≥45.0 kg for females.
Key exclusion criteria (42 listed)
- PATR A:
- PART B：
- <!-- -->
- <!-- -->
- 1) Complete blood count: absolute neutrophil count <1.0×10⁹/L, platelets <30×10⁹/L, white blood cells <2.0×10⁹/L, hemoglobin <75 g/L; 2) Blood chemistry: ALT and/or AST >5.0× ULN, total bilirubin >3.0× ULN; eGFR <60 mL/min/1.73 m²; 3) Coagulation function: international normalized ratio (INR) >1.5; 4) Urinalysis: urine protein ≥1+ and the investigator determines that the participant is unsuitable for the trial; 8. Individuals with a history of drug abuse or drug addiction within 1 year before screening, or with positive alcohol breath test or drug abuse test at screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| placebo GLR1075 VehicleSingle dose of intravenous infusion | Drug | placebo GLR1075 Vehicle |
| Human Serum Albumin(HSA)human albumin injection multiple doses of intravenous infusion | Drug | Human Serum Albumin(HSA) |
| GLR1075 Injectionrecombinant human albumin injection single dose or multiple doses of intravenous infusion | Drug | GLR1075 Injection |
Primary outcome
Number of AEs, number of AE episodes, and incidence rate of AEs
Time frame: Day1-Day 90 for PART A,Day1-Day 132 for PART B,Day1-Day 104 for PART C
7 secondary outcomes
Pharmacokinetics parameters-AUC0-t
Time frame: Day 1-Day 90 for Part A,Day 1-Day132 for Part B
Pharmacokinetics parameters-Cmax
Time frame: Day 1-Day90 for Part A,Day 1-Day132 for Part B
Pharmacokinetics parameters-Tmax
Time frame: Day 1-Day 90 for Part A,Day 1-Day132 for Part B
Pharmacodynamic parameters-serum albumin
Time frame: Day 1-Day 90 for Part A, Day 1-Day132 for Part B, Day 1-Day104 for Part C
Pharmacodynamic parameters-Plasma colloid osmotic pressure
Time frame: Day 1-Day 30 for Part A,Day 1-Day102 for Part B,Day 1-Day104 for Part C
Efficacy end point-serum albumin level
Time frame: Day 1-Day15 for Part C
Immunogenicity-ADA
Time frame: Day 1-Day 90 for Part A，Day 1-Day132 for Part B，Day 1-Day104 for Part C
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yunda Zhuge contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Human Serum Albumin(HSA) and GLR1075 Injection in people with Hypoalbuminemia in Cirrhotic Ascites, run by Gan & Lee Pharmaceuticals. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 42 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chenchen He (010-56456739, chenchen.he@ganlee.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of AEs, number of AE episodes, and incidence rate of AEs (time frame: Day1-Day 90 for PART A,Day1-Day 132 for PART B,Day1-Day 104 for PART C). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026; AzTrials last refreshed its copy on 1 Nov 2026.